Literature DB >> 23849958

Comparative TQT analysis with three fully-automated platforms: comparison to core laboratory semi-automated results.

Olivier Meyer1, Gerard Greig, Henry H Holzgrefe.   

Abstract

BACKGROUND AND
PURPOSE: Technological advances in machine-read QT measurement now enable detailed and precise cardiac repolarization assessments. This study assessed the applicability of three state-of-art ECG measurement applications to provide reliable continuous analyses from data obtained in a positive thorough QT study previously characterized with sparse semi-automated measurements performed by an ECG core laboratory.
METHODS: Continuous RR, QT, QTc measurements, and individual QT/RR relationships and their associated intra- and inter-subject variability were derived in parallel with BioQT, Ponemah PRO, and WinAtrec analysis software.
RESULTS: Despite slight vendor-specific differences in measurement variability and QTc, all machine-read methods demonstrated requisite assay sensitivity and yielded similar conclusions in accordance with SA analysis.
CONCLUSIONS: Three commercially available ECG analytical software applications reliably detected the drug-induced QT prolonging effects and replicated the SA core-laboratory conclusions, with greatly improved temporal resolution and reduced analytical costs. With broader experience, these data suggest that current SA methodologies could be effectively replaced by fully automated ECG analysis.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ECG core laboratory; Fully-automated QT analysis; QT measurement; Thorough QT study

Mesh:

Year:  2013        PMID: 23849958     DOI: 10.1016/j.jelectrocard.2013.06.002

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  1 in total

1.  Man versus Machine: Comparison of Automated and Manual Methodologies for Measuring the QTc Interval: A Prospective Study.

Authors:  Jean T Barbey; Margaret Connolly; Brenda Beaty; Mori J Krantz
Journal:  Ann Noninvasive Electrocardiol       Date:  2015-05-04       Impact factor: 1.468

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.